



Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	June 14, 2010 May 11, 2012, December 22, 2016

## **Oxandrin<sup>®</sup> (oxandrolone)**

**LENGTH OF AUTHORIZATION:** Up to six months

**CLINICAL NOTES:** Oxandrolone is indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of bone pain frequently accompanying osteoporosis.

### **REVIEW CRITERIA:**

- Weight gain, adjunctive treatment (prolonged administration of corticosteroids, chronic infections, extensive surgery or severe trauma).
- Bone pain associated with osteoporosis.

### **DOSING AND ADMINISTRATION:**

- Weight gain, adjunct treatment for children:
  - up to 0.1mg/kg/day divided two to four times daily.
- For adults weight gain adjunct treatment or bone pain associated with osteoporosis:
  - 2.5mg to 20mg given in 2 to 4 divided doses daily.